Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07717892

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

Conditions: ADHD

Sex: All

Ages: 12 Years – 17 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 468

Sponsor: Axsome Therapeutics, Inc.

Location: Clinical Research Site Dothan Alabama

Summary

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \

Eligibility Criteria

Inclusion Criteria: * Male or female, aged 12 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07717892). StuddyBuddy aggregates publicly available trial information.